retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Structural insights into the triple

Rigonal Insights U.S

Verdict at a Glance Semaglutide is the established gold standard with FDA approval, proven cardiovascular benefit, extensive clinical data, and multiple formulation options

What was once a relatively contained therapeutic class within endocrinology has expanded into a dual-purpose platform that operates across two distinct clinical domains

Eli Lilly's oral GLP-1 pill may help people with Type 2 diabetes lose 'significant' weight, study finds Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 pounds or more than 10% of their body weight on average, according to new data released Tuesday morning

Ann Pharmacother